Pharmaceutical Licensing & Asset Scouting Services

We support a number of companies in their pharmaceutical in-licensing activities, helping them develop strategies to leverage their strengths and achieve their corporate objectives. We also provide ongoing licensing support, working alongside the client’s internal efforts to generate a flow of new opportunities. Such activities include:

  • Working with the client’s global scouting team to identify companies and assets not yet appearing in industry pipeline databases
  • Contacting companies that fit our client’s criteria to ascertain their interest in a partnership
  • Targeted and regular attendance at partnering and scientific conferences
  • Scanning of new and recent literature to identify emerging opportunities
  • Outreach and networking with tech transfer offices, our industry contacts and licensing professionals

Recent examples of our work include supporting the search & evaluation team of a large pharma company to identify new opportunities in immuno-oncology, orphan diseases, immunology, cardiovascular and fibrosis, as well as an engagement with an emerging company backed by Versant Ventures and Celgene, for whom we have conducted an extensive global search for first-in-class antibodies over a 12+ month period. Many of our scouting relationships are ongoing and are all non-exclusive.

 

Looking to partner or to in- or out-license your assets? Reach out to us today and let us help you build a successful partnership. 


Featured Pharmaceutical In-Licensing Case Studies:

I. Pharma scouting for new antibody therapeutics

Challenge: A well-capitalized biotech company focused on developing antibody therapeutics for cancer and fibrosis needed to find new preclinical assets to in-license, with a particular focus on immune-oncology. A far-reaching search would be required to find the right match.

Solution: Over the course of two years, we conducted a systematic, global pharmaceutical scouting project through channels that included scientific literature, databases of grants and patents; tech transfer offices and scientific societies.

We used several industry pipeline databases to identify and contact academics, biotech startups and existing companies with novel or fast-follower preclinical stage antibodies.

In addition to desk research, we attended numerous local and international networking and biotech partnering events to scout for licensing opportunities on behalf of the client.

Having exhausted opportunities which had been published, we then wanted to find assets that were not yet in the public domain. We launched a scientific outreach campaign, sending individual, personalized emails to over 35,000 cancer researchers around the world.

We also deployed artificial intelligence and machine learning to scour and monitor the scientific literature to find scientific papers that described assets that fit our client’s criteria.

Our search and outreach identified several new in-licensing opportunities for our client, which are currently under due diligence or deal term negotiation.

 

II. Sourcing licensing opportunities to supplement internal pipeline development

 

Challenge: A pharmaceutical company that pioneered peptide pharmaceutical products, and a leader in reproductive medicine and women’s health, gastroenterology, and urology, had recently made the strategic decision to increase its in-licensing activities in order to supplement its internal pipeline development. While the company has an innovation sourcing team with coverage in Europe, China, and US west coast, it was recognized that a fresh pair of ‘boots on the ground’ in the US would support in-licensing opportunities. Alacrita was therefore engaged to conduct scouting activities, focusing on therapeutic assets and biomarkers in urology, hepatology, gastrointestinal disorders (particularly inflammatory bowel disease) and reproductive and women’s health. Alacrita scouted for assets significantly differentiated from existing agents (first-in-class, innovative assets), all the way from discovery phase of development to Phase I clinical development.

Solution: Alacrita’s activities included scanning new and recent literature to identify emerging opportunities; searches of grants, deals, and pipeline databases; outreach and networking with biotech and pharma companies, industry contacts, large pharma as well as licensing professionals and technology transfer offices; and finally regular attendance at meetings and conferences which were likely to attract new biotech companies in early preclinical or clinical stage of development. We worked closely with the client’s team to identify important targets and pathways of interest and took an iterative approach to adjust our search criteria, such that they align with client’s evolving interests throughout the engagement. We tracked opportunities in a document that was updated and shared on a weekly basis. Licensing opportunities that Alacrita identified as appropriate for the incubator were delivered on a rolling basis.